News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
This month marks a major US milestone for biosimilar medicines as five years ago, September 2015, saw the first biosimilar made available to US patients – the Sandoz developed Zarxio (filgrastim-sndz).
Sanofi and GSK will provide the EU with up to 300 million doses of their COVID-19 vaccine candidate, with the agreement suppporting scale-up of manufacturing capabilities in several European countries.
Roche has acquired four-year-old biotech start-up Inflazome, a company developing orally available drugs targeting inflammasomes.